An Open-Label, Long-Term Extension Study of the Safety of Somavaratan (VRS-317) in Adults With Growth Hormone Deficiency (GHD)
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2017
At a glance
- Drugs Somavaratan (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions
- Sponsors Versartis
- 07 Jun 2017 Biomarkers information updated
- 30 Jan 2017 According to Versartis Media release, data will be presented at the Endocrine Society 2017 annual meeting.
- 26 Sep 2016 According to Versartis Media release data from the Phase 2 stage will be submitted to a scientific conference during the first half of 2017.